Financial Performance - Revenue for the year ended June 30, 2025, was HK$726,949,000, a decrease of 2.9% from HK$748,489,000 in 2024[10] - EBITDA increased by 2.7% to HK$87,025,000 from HK$84,776,000, reflecting improved operational efficiency[10] - Adjusted EBITDA rose significantly by 21.1% to HK$94,878,000 compared to HK$78,357,000 in the previous year[10] - Profit for the year decreased by 9.4% to HK$31,916,000 from HK$35,217,000 in 2024[10] - Profit attributable to owners of the Company fell by 22.6% to HK$31,440,000 from HK$40,643,000[10] - Basic and diluted earnings per share decreased by 21.7% to HK$3.98 from HK$5.08[10] - Proposed final dividend per share is HK$1.90, down 5.0% from HK$2.00 in the previous year[10] - Interim dividend per share increased by 7.7% to HK$1.40 from HK$1.30[10] - The Company reported a profit before tax of HK$40,499,000, a slight decrease of 0.3% from HK$40,624,000[10] - For the fiscal year 2025, the EBITDA margin increased to 12.0%, up by 0.7 percentage points from 11.3% in 2024[12] - Adjusted EBITDA margin improved to 13.1%, reflecting a significant increase of 2.6 percentage points compared to 10.5% in the previous year[12] - Net profit margin decreased to 4.4%, down by 0.3 percentage points from 4.7% in 2024[12] Assets and Liabilities - Total assets as of June 30, 2025, were HK$1,095,325, a decrease of 1.0% from HK$1,106,823 in 2024[12] - Cash, bank balances, and deposits increased by 18.2% to HK$302,836 from HK$256,139 in 2024[12] - Net current assets rose by 22.4% to HK$267,681, compared to HK$218,719 in the previous year[12] - Shareholders' funds increased by 2.3% to HK$742,632 from HK$725,942 in 2024[12] - Right-of-use assets as of June 30, 2025, were approximately HK$96.5 million, down from HK$107.2 million in FY2024, representing about 8.8% of the Group's total assets[191][195] - Goodwill as of June 30, 2025, was approximately HK$156.6 million, a decrease from HK$164.2 million in FY2024, representing about 14.7% of the Group's total assets[193][196] - Investments at fair value through other comprehensive income amounted to approximately HK$40.3 million as of June 30, 2025, an increase from HK$30.5 million in FY2024[199] - Financial assets at fair value through profit or loss were approximately HK$38.9 million as of June 30, 2025, a decrease from HK$41.1 million in FY2024[199] - The total value of investments at fair value through other comprehensive income and financial assets at fair value through profit or loss represented about 7.2% of the Group's total assets as of June 30, 2025, compared to 6.5% in FY2024[199] Strategic Initiatives - The company announced the establishment of a new community medical healthcare center in Guangdong Province as part of its Greater Bay Area strategy[22] - Investments in smart clinic systems and AI-assisted diagnostics are aimed at enhancing operational efficiency and supporting proactive health management[22] - The focus on preventive medicine includes health screenings and wellness initiatives, aiming to attract more patients and strengthen revenue streams[22] - The corporate healthcare solutions business now serves over 1.3 million end users across more than 1,000 service points in Hong Kong, Macau, and Chinese Mainland[31] - The company continues to strengthen its third-party administration (TPA) services to provide a more comprehensive and integrated healthcare service[37] - The company is tailoring corporate healthcare plans to enrich employee benefits while balancing cost budgets for related companies[39] - The company is focused on ensuring that every patient interaction is supported by the best that modern medicine can offer[42] - The Corporate Solutions and Managed Care division remains a robust core of the business, leveraging data analytics to enhance client relationships and achieve high retention rates[46] - A new Clinic Management System (CMS) was launched, achieving a fully paperless workflow across outpatient centers, alongside the Electronic Pre-Approval (EPA) platform for seamless integration[47] - The establishment of a new TPA office and a Hong Kong-invested health station in Foshan marks a significant step in expanding regional footprint and service capabilities[48] - The company is actively exploring strategic partnerships and M&A opportunities across the Greater Bay Area and other regions in Chinese Mainland[48] - UMP aims to create a seamless, patient-centric journey across all service lines while investing in the next generation of clinical and managerial leaders[54] - The company is committed to evolving service models to meet changing market needs and strengthening its impact across the Greater Bay Area and beyond[54] Market Challenges and Responses - The company faced a challenging macroeconomic environment, impacting corporate decision-making and operational priorities[77] - The demand for Immigration Medical Examination (IME) services significantly declined due to economic downturn and geopolitical tensions in 2025[135][140] - The full reopening of borders between Hong Kong and Mainland China is expected to unleash pent-up demand for high-quality medical services[99] - The company is increasing its focus on the small and medium enterprise sector, which has shown resilient growth and a strong appetite for structured benefits packages[100] - The extensive and curated network of premium healthcare providers in Hong Kong serves as a critical competitive advantage for the company[101] - The company is engaging existing clients to enhance their plans for remaining employees, thereby maintaining per-member revenue[100] - Revenue in Hong Kong and Macau clinical healthcare services decreased by 4.3%, while operating profit increased by 16.4% due to lower costs[111] - Strategic focus for FY2025 on operational excellence and cost optimization, leading to stable and profitable growth[112] Growth and Development - The company achieved high-single-digit revenue growth, primarily driven by increased utilization of comprehensive healthcare plans and a surge in demand for related clinical medical services[88] - Profit margins expanded due to operational efficiencies and the scalable nature of the TPA platform, showcasing the strategic value of the integrated model[88] - The company focused on building a one-stop healthcare ecosystem by expanding partnerships beyond core insurance providers to include wellness tech firms and pharmaceutical providers[94] - A significant increase in the utilization of insured healthcare plans was observed, reflecting a shift towards quality and security during uncertain times[87] - The company successfully launched enhanced and modular plan options, allowing clients to enrich employee benefits while controlling costs[83] - The restructuring and integration of medical imaging and testing centers began to show results in FY2025, contributing significantly to revenue and profit growth[66] - The newly established medical imaging centres contributed positively to revenue growth, indicating a key growth vector for the future[75] - The company is focused on digital transformation, including launching a comprehensive member mobile app for easier access to services and personalized health tracking[161] - Future strategies include exploring geographic expansion in the Asia-Pacific region and introducing new service lines such as advanced mental health programs[162] - Continued investment in partnerships, technology, and regional expansion is identified as key pillars for growth and sustainability[163]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任 何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 UMP HEALTHCARE HOLDINGS LIMITED 噛⠡桂⛪涐⭒㯡洒軴⠑ 荵㪇 汇㯒啯ㅤ躳▌踁偽逓㯡洒軴 ⠑荶 荵嚎⋚⊿屽莇722荶 補充公告 有關醫療服務框架協議的 持續關連交易 及 有關附屬公司層面醫療服務的 歷史持續關連交易 謹此提述聯合醫務集團有限公司（「本公司」）日期為2025年7月31日的公告（「該公 告」），內容有關（其中包括）協議連同其項下擬進行的交易構成本公司的持續關連 交易。 本公司謹此就(i)協議；及(ii)有關仁德醫療相關服務及聯合醫務醫療相關服務的歷 史交易提供進一步資料。 除本公告另有指明外，本公告所用詞彙與該公告所界定者具有相同涵義。 協議 仁德醫療相關服務及聯合醫務醫療相關服務的服務範疇 仁德醫療相關服務主要包括由仁德醫健集團聘用的專科醫生及外科專科醫生所提 供的醫療服務，而聯合醫務醫療相關服務則主要包括向仁德醫健集團提供化驗及 影像服務等輔助醫療服務及由全科 ...

Core Viewpoint - The company has entered into a medical service agreement with Chow Tai Fook Life Insurance, which will enhance its service offerings and potentially increase revenue streams [1] Group 1: Agreement Details - The agreement is set to commence on January 1, 2026, and will last for two and a half years [1] - The agreement involves the provision and management of medical services to members and/or family members of Chow Tai Fook Life Insurance [1] Group 2: Company Structure - The agreement is established through the company's indirect wholly-owned subsidiary, United Medical Professional [1]

Core Viewpoint - United Medical (00722.HK) has entered into a medical service agreement with Chow Tai Fook Life Insurance, which will commence on January 1, 2026, and will last for two and a half years [1] Group 1 - The agreement involves United Medical Professional (or its applicable subsidiaries) providing and managing medical services for members of Chow Tai Fook Life Insurance and/or their family members [1] - The contract is set to be renewed for a period of two and a half years starting from January 1, 2026 [1]

联合医务(00722)发布公告，于2025年10月9日，本公司间接全资附属公司联合医务专业与周大福人寿订 立2026年周大福人寿医疗服务协议，内容有关由联合医务专业(或其适用的联属公司)向周大福人寿成员 及/或周大福人寿家庭成员提供及管理医疗服务，该协议自2026年1月1日起续期两年六个月。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任 何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 有關2026年周大福人壽醫療服務協議之 持續關連交易 獨立董事委員會及獨立股東之獨立財務顧問 2026年周大福人壽醫療服務協議 董事會宣佈，於2025年10月9日，本公司間接全資附屬公司聯合醫務專業與周大 福人壽訂立2026年周大福人壽醫療服務協議，內容有關由聯合醫務專業（或其 適用之聯屬公司）向周大福人壽成員及╱或周大福人壽家庭成員提供及管理醫 療服務，該協議自2026年1月1日起續期兩年六個月。 UMP HEALTHCARE HOLDINGS LIMITED 噛⠡桂⛪涐⭒㯡洒軴⠑ 荵㪇 汇㯒啯ㅤ躳▌踁偽逓㯡洒軴 ⠑荶 荵嚎⋚⊿屽莇722荶 上市規則之涵義 周大福人壽為周大福創建之間接全資附屬公司，周大福創建為周大福企業之附 屬公司，而周大福企業為本公司之主要股東。因此，周大福人壽為本公司之關 連人士，而根據上市規則第十四A章，2026年周大福人壽醫療服務協議項下擬 進行之交易構成本公司之持續關連交易 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年9月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 聯合醫務集團有限公司 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00722 | 說明 | | | | | | | | | 已發行股份（不包括庫存股份）數目 | | 庫存股份數目 | | 已發行股份總數 | | | 上月底結存 | | | 810,955,244 | | 0 | | 810,955,244 | | 增加 / 減少 (-) | | | 0 | | 0 | | | | 本月底結存 | | | 810,955,244 | | 0 | | 810,955,244 | 第 2 頁 共 10 頁 v 1.1.1 呈交日期: 2025年10月6日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香 ...

格隆汇9月30日丨联合医务(00722.HK)公告，由于2022年医疗服务协议将于2025年9月30日届满，公司间 接全资附属公司联合医务专业与周大福人寿订立2025年周大福人寿医疗服务协议，内容有关由联合医务 专业(或促使其适用联属公司)向周大福人寿成员及╱或周大福人寿家庭成员提供及管理医疗服务。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任 何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 UMP HEALTHCARE HOLDINGS LIMITED 1 由於根據2025年周大福人壽醫療服務協議擬進行之持續關連交易之建議交易上 限計算之最高適用百分比率（定義見上市規則第14.07條）高於0.1%但低於5%， 根據2025年周大福人壽醫療服務協議擬進行之持續關連交易須遵守申報、年度 審核及公告規定，但根據上市規則第14A.76(2)條獲豁免遵守通函（包括獨立財 務建議）及股東批准之規定。 茲提述本公司日期為2022年10月1日、2022年10月7日及2023年3月16日之公告，內 容有關2022年醫療服務協議。 噛⠡桂⛪涐⭒㯡洒軴⠑ 荵㪇 汇㯒啯ㅤ躳▌踁偽逓㯡洒軴 ⠑荶 荵嚎⋚⊿屽莇722荶 有關2025年周大福人壽醫療服務協議之 持續關連交易 2025年周大福人壽醫療服務協議 由於2022年醫療服務協議將於2025年9月30日屆滿，本公司間接全資附屬公司聯 合醫務專業與周大福人壽訂立20 ...

（原标题：联合医务(00722)将于1月9日派发末期股息每股0.019港元） 智通财经APP讯，联合医务(00722)发布公告，将于2026年1月9日派发截至2025年6月30日止年度的末期 股息每股0.019港元。 ...